Weight loss drugs like Ozempic are among the most requested drugs on the market – prescribed for everything, from diabetes to weight loss.
But an increasing number of patients claim that the Ozempic can be accompanied by a terrifying side effect: an irreversible loss of vision.
Edward Fanelli, a former Freehold entrepreneur, New Jersey, said he had been prescribed from Ozempic to manage his diabetes, but in a few months, his vision had become dark – forcing him to abandon his career.
“Not even six to eight months later, me, from nowhere, I couldn’t see my right eye,” he said. “I could not try to take the work of markets, worried about cutting my fingers.”
Fanelli says that it was diagnosed with an anterior non -arteritic anterior ischemic neuropathy (naïon), a sudden condition on the plateau without healing.
He is the first patient in New Jersey to bring legal action before the State Tribunal against the manufacturers of Ozempic, saying that it has never been warned that successful drugs could lead to irreversible loss of vision. “If they had told me a chance that I could lose my vision, I would not have taken it. I don’t care-the weight loss would have done by myself,” he said.
He is not alone.
Goldstein claims that drug manufacturers have not warned patients.
“This is the knot of this case, people are not warned about it. What did the doctor know? What was the patient knew? No one knew,” he said.
Goldstein says he will pressure for warning labels and updated compensation so that future patients are not negatively affected by a medication they thought of helping.
A spokesperson for Novo Nordisk published the following statement:
“Naiton is a very rare eye disease, and it is not an undesirable reaction for the marketed formulations of Sémaglutide (Ozempic®, Rybelsus® and Wegovy®) in accordance with approved labels. After an in -depth assessment of studies of the University of South Denmark and the Nodo Nordisk of internal safety of the Nordisk is of opinion.
Novo Nordisk, on his part, carried out an analysis through randomized controlled clinical trials with GLP-1 receptor agonists, including an evaluation as a blind ophthalmologist to confirm the niton diagnostics. These data do not suggest a causal relationship between the use of GLP-1 RA and Naion events.
Patient safety is an absolute priority for Novo Nordisk, and we take all reports on adverse events in the use of our drugs very seriously. This also concerns eye conditions, which are well -known comorbidities for people with diabetes. Any decision to start treatment with drugs only on prescription must be made in consultation with a health professional who should carry out a risk assessment for the patient in question, weighing the advantages of treatment with potential risks. “”
